Amelioration of acute graft vs host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody.
Lethal acute graft vs host disease (GVHD) elicited by minor histocompatibility antigens was studied in a murine model of bone marrow transplantation (B10.BR----CBA). The severity of GVHD was reduced by both clinical and histologic parameters when transplant recipients received injections of a monoclonal antibody directed against the interleukin 2 receptor. This study suggests that anti-interleukin 2 receptor antibodies may be useful in clinical marrow transplantation and provides additional evidence that monoclonal antibodies that block T cell function in vitro may be of therapeutic value in vivo.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001323:Autoantibodies / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology* / Q000628:therapy; D007167:Immunotherapy; D007376:Interleukin-2 / Q000276:immunology*; D051379:Mice; D008912:Minor Histocompatibility Loci; D011971:Receptors, Immunologic / Q000276:immunology*; D015375:Receptors, Interleukin-2; D012867:Skin / Q000276:immunology
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D007376:Interleukin-2; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2